LEO Pharma showcases promising results from DELTA 3 trial at AAD Congress
In a significant development within the field of medical dermatology, LEO Pharma A/S, a global leader renowned for its commitment to advancing dermatological care, presented ... Read More
UCB announces positive 48-week results for BIMZELX in Hidradenitis Suppurativa studies
At the 2024 American Academy of Dermatology (AAD) Annual Meeting in San Diego, California, UCB, a leading global biopharmaceutical company, shared promising 48-week post-hoc analyses ... Read More